Ocular Therapeutix (OCUL) Net Income towards Common Stockholders (2013 - 2026)

Ocular Therapeutix has reported Net Income towards Common Stockholders for 14 years, with the latest figure at -$79.5 million in Q2 2026.

• Net Income towards Common Stockholders for Q2 2026 came in at -$79.5 million, down 18.23% year-over-year; the trailing twelve-month figure through Jun 2026 was -$302.7 million (down 35.84% YoY), and the FY2025 annual result was -$544.1 million, down 44.42% from the prior year.
• Net Income towards Common Stockholders advanced to -$79.5 million in Q2 2026, from -$90.1 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$16.9 million in Q4 2023 and troughed at -$90.1 million in Q1 2026.
• A 5-year average of -$43.0 million and a median of -$40.7 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The widest annual swing landed in 2022, when Net Income towards Common Stockholders gained 10.95%; it then plunged 190.56% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$18.4 million in 2022, then rose by 8.12% to -$16.9 million in 2023, then plunged by 190.56% to -$49.0 million in 2024, then sank by 33.13% to -$65.2 million in 2025, then decreased by 21.77% to -$79.5 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$79.5 million in Q2 2026, -$90.1 million in Q1 2026, and -$65.2 million in Q4 2025.